Clear Search

Showing 2 result for “Gudbjornsson B”.

September 2023
July 2022

Secukinumab治療は TNF阻害薬よりも感染症リスクが高いか?北欧からの観察研究

Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac358

Glintborg B et al, highlight in their recent research from the Nordic countries, that there is a low frequency of hospitalised infections during treatment with secukinumab or TNFi in patients with SpA and PsA. In clinical practice, secukinumab was found to double absolute risk of 1st year hospitalised infection compared with adalimumab, with the other TNFi treatments falling in between.